Pharmaceutical

VTE risk elevated in Swedish patients hospitalised for Covid-19

In this 2023 study, Sjoland and other researchers found an elevated excess risk of VTE after 180 days in patients hospitalised for Covid-19.

Sep 5, 2023 - 20:00
VTE risk elevated in Swedish patients hospitalised for Covid-19
In this 2023 study, Sjoland and other researchers found an elevated excess risk of VTE after 180 days in patients hospitalised for Covid-19.
Read the original article

Tags:

Previous Article

New 2023 guidelines for the management of cardiomyopathies

Next Article

invIOs’s cell therapy secures Austrian Government grant for Phase Ib trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA accepts Merck’s Keytruda plus Padcev sBLA to treat urothelial cancer

FDA accepts Merck’s Keytruda plus Padcev sBLA to treat ...

Dec 2, 2023

New UK intracellular drug delivery centre to support RNA development

New UK intracellular drug delivery centre to support RN...

Jun 1, 2023

Specialised Therapeutics partners with Treeway to license ALS drug

Specialised Therapeutics partners with Treeway to licen...

Aug 28, 2023